Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia by Xia Pu, Mark Sale, Feng Yang, Yi Zhang, John D. Davis, Nidal Al‐Huniti

Connect to this object online.

Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma by Li Zhang, Yue Gao, Meng Li, Christine Xu, John D. Davis, Vanaja Kanamaluru, Qiang Lu

Connect to this object online.

Dupilumab: Mechanism of action, clinical, and translational science by Marc R. McCann, Matthew P. Kosloski, Christine Xu, John D. Davis, Mohamed A. Kamal

Connect to this object online.

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer by Jenny‐Hoa Nguyen, Daniel Epling, Nancy Dolphin, Anne Paccaly, Daniela Conrado, John D. Davis, Nidal Al‐Huniti

Connect to this object online.

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab by Masood Khaksar Toroghi, Jim Bosley, Lyn M. Powell, Yi Zhang, Feng Yang, Xia Pu, John D. Davis, Nidal Al‐Huniti

Connect to this object online.

Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials by Matthew P. Kosloski, George D. Kalliolias, Christine R. Xu, Sivan Harel, Ching‐Ha Lai, Wenjun Zheng, John D. Davis, Mohamed A. Kamal

Connect to this object online.

Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study by Andrew Gewitz, Jeanne Mendell, Yuhuan Wang, Charles Harris, Benjamin A. Olenchock, Simona Podgrabinska, Wenjun Zheng, An Zhao, Hao Pan, Frédéric Vanhoutte, John D. Davis

Connect to this object online.

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis by Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, Ronda Rippley, A. Thomas DiCioccio

Connect to this object online.

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics by Mohamed A. Kamal, Robert Dingman, Claire Q. Wang, Ching‐Ha Lai, Manoj Rajadhyaksha, Michelle DeVeaux, Jamie M. Orengo, Allen Radin, John D. Davis

Connect to this object online.

Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis by Mohamed A. Kamal, John D. Davis, Pavel Kovalenko, Kamal Srinivasan, Eric L. Simpson, Takeshi Nakahara, Makoto Sugaya, Atsuyuki Igarashi, Marius Ardeleanu, Christine Xu, Kazuhiko Arima

Connect to this object online.

A drug‐disease model for predicting survival in an Ebola outbreak by Masood Khaksar Toroghi, Nidal Al‐Huniti, John D. Davis, A. Thomas DiCioccio, Ronda Rippley, Alina Baum, Christos A. Kyratsous, Sumathi Sivapalasingam, Joel Kantrowitz, Mohamed A. Kamal

Connect to this object online.

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies by Min Zhu, Kara Olson, Jessica R. Kirshner, Masood Khaksar Toroghi, Hong Yan, Lauric Haber, Craig Meagher, Dina M. Flink, Srikanth R. Ambati, John D. Davis, A. Thomas DiCioccio, Eric J. Smith, Marc W. Retter

Connect to this object online.

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials by Matthew P. Kosloski, Emma Guttman‐Yassky, Michael J. Cork, Margitta Worm, Dong‐Ho Nahm, Xiaoping Zhu, Marcella K. Ruddy, Sivan Harel, Mohamed A. Kamal, Hélène Goulaouic, Christine R. Xu, Elena Avetisova, John D. Davis, Michael C. Nivens, Arsalan Shabbir, Allen Radin

Connect to this object online.